NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies |
|
|
| Completed | 4 | 337 | Europe, Canada, Japan, US, RoW | Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR | RECORDATI GROUP | Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS | 07/23 | 07/23 | | |
NCT01253161: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) |
|
|
| Completed | 2 | 29 | US | Pasireotide Long Acting Release (LAR), SOM 230 | H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals, RECORDATI GROUP | Neuroendocrine Tumors, Carcinoid Tumors | 10/21 | 03/23 | | |